COVID treatment: Henry Ford Health works to increase access to monoclonal antibody therapy
Published:
Tags:
A laboratory worker at Eli Lilly prepares a solution used to manufacture bamlanivimab, a new monoclonal antibody therapy for COVID-19. When given within 10 days of a positive COVID-19 test, these man-made antibodies may help lessen the severity of the disease and reduce the need for hospitalization in people most at risk of developing severe COVID-19. (Provided by UF Health)
Henry Ford Health System announced Thursday, in partnership with the U.S. Department of Health and Human Services (HHS), that it is boosting access to monoclonal antibody therapy in southeast Michigan.
South Florida doctors tout potentially life-saving COVID-19 therapy
Cleveland Clinic Martin Health
and last updated 2021-04-14 16:47:09-04
With so many people waiting to get vaccinated and covid cases continuing to rise, local doctors want you to know about a potential life-saving treatment.
It s called monoclonal antibody therapy.
According to the Food and Drug Administration, it is antibodies that are lab-produced proteins that mimic the immune systemâs ability to fight off harmful viruses.
Itâs currently under emergency use authorization by the FDA and the drug is a combination of Bamlanivimab and Etesevimab.
The therapy is for adults age 65 or older or people with pre-existing health conditions who are at high risk for progressing to severe COVID-19.
Syngene brings out novel approach to treat acute myeloid leukaemia
Syngene brings out novel approach to treat acute myeloid leukaemia
24 February 2021 | News The article details important findings and solutions that were brought forth by the scientists in the novel approach for the treatment of Acute Myeloid Leukaemia (AML)
Source credit: Shutterstock
Two Syngene scientists, Vijaykumar Chennupati and Balaji Ramachandran, co-authored an article titled ‘Selective recruitment of γδ T cells by a bispecific antibody for the treatment of acute myeloid leukaemia’ that got published in Leukemia, a prestigious international journal from the Nature Publishing Group. The scientists designed and conducted the experiments and performed the data analysis and helped with interpretation.
Monoclonal anti-body therapy has been used for more than 30 years to treat cancer and infectious diseases, and hospitals have been using it to treat COVID-19 patients with success since the FDA emergency authorization.
“Millions of years of evolution have taught us how to fight a virus, and we’re taking that technology, that ability, that the human body has, and we’re just duplicating it,” said Chief Medical Officer for Palomar Health, Omar Khawaja, MD, MBA.
Normally, when you get a virus your body has an immune response and creates antibodies, but that doesn t happen with COVID-19 as it is a new virus.
While we still donât know everything about the novel coronavirus, we know a lot more than we did when the pandemic first hit.
Dr. Paula Aucoin Blagg is semiretired as an infectious diseases specialist, but after getting a call in early March, she has been filling in at Berkshire Medical Center to help the hospital meet the need for treatment.
In a Tuesday afternoon talk, Blagg discussed the current picture for COVID-19 vaccinations and treatments. Although medical diagnosis and options for treatment have improved greatly, there still is no âmagic bulletâ for the disease, Blagg said.
âFace masks [and] physical distancing recommendations will need to be continued for the foreseeable future,â she said. âAnd worldwide vaccine goals will require multiple vaccine types, multiple distribution strategies and multinational cooperation.â
Atlantic General Hospital giving out Monoclonal Antibody Therapy, could prevent a spike in COVID-19 hospitalizations wmdt.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from wmdt.com Daily Mail and Mail on Sunday newspapers.
Outlook on the Trispecific Antibodies Global Market to 2024 - Featuring AbbVie, Affimed and Biotheus Among Others
December 10, 2020 05:23 ET | Source: Research and Markets Research and Markets Dublin, IRELAND
ResearchAndMarkets.com s offering.
Trispecific cancer antibody therapy market at an early phase of development has crossed a long path to get recognized and appreciated as one of the most innovative and important breakthrough and achievement ever done in the complete cancer therapeutics sector. The development of antibody capable of targeting three different targets with the help of recombinant biotechnology is leading to the further explication of the market that monoclonal and bispecific antibodies were once performing at a very accelerated rate. Overall scientific information about the antibody targeting and how increasing the number of targeting molecules can increase the efficacy of the treatment triggered the researc